1,853 material Form 8-K filings that 1,500 companies we cover made with the SEC in September 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Xylem entered into a new five-year, $1.5 billion senior unsecured revolving credit facility on September 8, 2026, and terminated its $1.0 billion facility from March 2023 at the same time. The company says the new facility will fund working capital and general corporate purposes, and no borrowings were outstanding on the filing date.
New facility: up to $1.5 billion, five years, available in U.S. dollars and Euros, with accordion increases of up to $500 million to a $2.0 billion maximum
Terminated 2023 facility: $1.0 billion, dated March 1, 2023, with citibank, N.A. as administrative agent
No borrowings outstanding under the new agreement as of September 8, 2026; loans carry a leverage-based covenant on total debt to EBITDA
Odyssey Therapeutics furnished a corporate presentation on Form 8-K, posted to its website on September 8, 2026. The deck covers Phase 2a monotherapy data for its oral RIPK2 inhibitor OD-001 in ulcerative colitis and preclinical data for its SLC15A4 inhibitor OD-002, and states $433 million in cash as of June 30, 2026, with runway into the second half of 2028. The filing contains no financial results, guidance, or new contracts; the presentation is company-prepared and its data are described as ongoing and subject to change.
Balance sheet of $433 million as of June 30, 2026, expected to fund operations into H2 2028
OD-001 Phase 2a monotherapy: 27% clinical remission rate in moderate-to-severe UC patients, with a -2.6 change in MMCS (p < 0.001), per presentation
Next OD-001 data disclosure expected at UEG in October 2026; OD-002 CTA filing expected in H2 2026
Zions Bancorporation announced that Brian Stringham, a 2003 hire and its current Assistant Corporate Controller, will succeed Jason Arbuckle as Senior Vice President and Corporate Controller, effective September 7, 2026. Stringham becomes the bank's principal accounting officer, and Arbuckle moves to Senior Director of Corporate Finance and Transformation. The change concerns the bank's top accounting role but the filing reports no financial results or compensation changes.
Brian Stringham, 51, succeeds Jason Arbuckle as Senior Vice President and Corporate Controller, effective September 7, 2026
Stringham will serve as the Bank's principal accounting officer
Arbuckle will become Senior Director of Corporate Finance and Transformation
Stringham has overseen SEC and regulatory reporting as Director of External Financial Reporting since 2020
Teleflex expanded its board from eight to nine directors and elected Sean M. Salmon to fill the new seat, effective September 8, 2026. Salmon previously led Medtronic's Cardiovascular portfolio, and the company says his appointment supports its governance and strategic priorities.
Board increased from eight to nine directors; Sean M. Salmon elected to fill the new seat on September 8, 2026
Salmon, age 61, founded consulting firm Zamboni Holdings, LLC in December 2025 and previously spent 21 years at Medtronic
At Medtronic, Salmon was Executive Vice President and President, Cardiovascular, from January 2021 to September 2025
Salmon joins the Growth and Operating Committee; he receives standard non-employee director compensation
X4 Pharmaceuticals posted an updated corporate presentation on its website on September 8, 2026, filed as Exhibit 99.1 to a Form 8-K. The filing reiterates the timeline for its pivotal Phase 3 4WARD study of mavorixafor in chronic neutropenia, with full enrollment expected in Q4 2026 and top-line data expected in H1 2028, and it reports cash of $208 million as of June 30, 2026.
Presentation dated September 8, 2026, posted to the Investors section of the company website
Full enrollment in the 4WARD Phase 3 study expected in Q4 2026; top-line data expected in H1 2028
Cash of $208 million and 145.6 million fully diluted shares outstanding as of June 30, 2026; cash runway expected into 2029
Bit Digital began presenting an investor deck to investors on September 9, 2026, and may use it at two September investment conferences. The deck is summary information with figures as of July 31, 2026, and it reports no new quarterly or annual financial results.
Presentations began September 9, 2026; the deck may be used at the Moody Capital conference on September 9-10 and the H.C. Wainwright conference on September 14-16, 2026.
The company reports 164,842.2 ETH/lsETH held, valued at about $306.7 million, using an ETH price of $1,860.35 as of July 31, 2026.
The deck shows a BTBT share price of $1.31 and an mNAV per share of $2.21, a 41% discount, as of July 31, 2026; mNAV is a non-GAAP metric.
Sound Point Meridian Capital, Inc. disclosed management's unaudited estimate that its net asset value per share was between $9.52 and $9.62 as of August 31, 2026. The filing provides a range rather than a single figure and does not compare the estimate with prior periods or explain changes in value.
Estimated NAV per share range: $9.52 to $9.62 as of August 31, 2026
Figures are management's unaudited estimate
Filed under Item 8.01 (Other Events) on September 8, 2026, signed by CEO Ujjaval Desai
Chime entered into a merger agreement to acquire Central Service Corporation (CSC), the parent of Stride Bank, N.A., for $590 million, subject to customary adjustments. Chime also raised its third-quarter and full-year 2026 guidance, and the deal is expected to close in the first half of 2027 after approvals from the OCC and the Federal Reserve. The acquisition would make Chime a bank holding company and give it its own bank charter.
Purchase price of $590 million, subject to adjustments for transaction expenses, certain dividends and preferred stock redemption
Expected close in the first half of 2027, subject to OCC and Federal Reserve approvals
Q3 2026 revenue guidance of $705 million, about 30% year-over-year growth; full-year revenue guidance of $2.76 billion to $2.77 billion
Full-year 2026 adjusted EBITDA guidance of $481 million to $489 million; Chime expects more than $100 million in net synergies
Nerdy Inc. disclosed that Chief Accounting Officer Kyle Callaway resigned, having notified the company on September 1, 2026, after accepting a position at another company. The company said the departure was not due to any disagreement over financial reporting, accounting policies, practices, or internal controls. Chief Financial Officer Atul Bagga will also serve as principal accounting officer.
Kyle Callaway resigned as Chief Accounting Officer and principal accounting officer; he notified the company on September 1, 2026.
Callaway has accepted a position at another company.
The company states the resignation was not related to any disagreement on financial reporting, accounting policies, practices, or internal controls.
CFO Atul Bagga will assume the principal accounting officer role upon Callaway's departure.
Estrella Immunopharma received a Nasdaq notice on September 1, 2026, stating its market value of listed securities fell below the $35 million minimum for 30 consecutive business days. The company has until March 1, 2027 to regain compliance, and the stock continues to trade on Nasdaq for now, but failure to comply could lead to delisting proceedings.
Nasdaq notice dated September 1, 2026 cites market value of listed securities below $35,000,000 for 30 consecutive business days, July 21 through August 31, 2026
Company does not meet Nasdaq's alternative standards for stockholders' equity of at least $2,500,000 or net income of at least $500,000
Compliance deadline is March 1, 2027; regaining compliance requires closing at $35,000,000 or more for at least ten consecutive business days
Common stock continues to trade on The Nasdaq Capital Market under the symbol ESLA
Worthington Steel GmbH, a subsidiary of Worthington Steel, Inc., signed a Domination and Profit and Loss Transfer Agreement (DPLTA) with Kloeckner & Co SE on September 8, 2026. The agreement takes effect only after Kloeckner shareholder approval and registration with the commercial register, no earlier than January 1, 2027, and registration may be delayed by German shareholder litigation. Outside Kloeckner shareholders may take a cash payment of EUR 11.00 per share or an annual payment of EUR 0.67 per share (EUR 0.66 net), and may challenge the terms in appraisal proceedings.
DPLTA signed September 8, 2026 between Worthington Steel GmbH and Kloeckner & Co SE, which follows the completion of Worthington Steel's voluntary takeover offer on June 3, 2026.
Kloeckner's extraordinary general meeting is expected October 23, 2026; approval requires at least 75% of the share capital represented.
Under the DPLTA, outside shareholders can elect EUR 11.00 per share in cash or an annual payment of EUR 0.67 per share (EUR 0.66 net).
Kloeckner shares were delisted from the Frankfurt Stock Exchange's regulated market effective August 12, 2026.
SUNation Energy and Suniva signed a First Amendment to their June 5, 2026 merger agreement on September 4, 2026, changing the conditions for closing and adding new stockholder approvals. The amendment also sets a $2,608,303 related party loan repayment or conversion plan at $2.26 per share, which depends on SUNation stockholder approval.
The amendment makes an increase in SUNation's authorized shares from 1 billion to 1.5 billion a closing condition, along with approval of share issuances tied to securities issued to Suniva lenders.
SUNation's closing net cash requirement changes from negative $1.5 million to negative $2.5 million, subject to adjustment for potential capital raises.
SUNation will use reasonable best efforts to repay or convert up to $2,608,303 in related party loans at a fixed conversion price of $2.26 per share; if stockholders do not approve the conversion, Suniva must repay the loans and accrued int
A consent letter limits further Suniva share issuances or committed issuances above 5% of its fully-diluted shares on a pro-forma basis without further SUNation written consent.
United Therapeutics entered an accelerated share repurchase agreement with Citibank to buy back about $477.6 million of its common stock, using the remainder of its $2 billion repurchase authorization. The company will pay the amount upfront on or around September 10, 2026, and will receive an initial delivery of about 719,376 shares, with final settlement expected in the fourth quarter of 2026.
Upfront payment of about $477.6 million to Citibank on or around September 10, 2026
Initial delivery of about 719,376 shares, about 75% of the shares expected under the agreement at the September 8, 2026 closing price
Final share count depends on the average daily VWAP during the term, less a discount; final settlement expected in Q4 2026
Company previously completed ASR agreements totaling $1.5 billion in March 2026 and bought $22.4 million in open-market purchases in Q3 2026
Suniva, which is to merge with SUNation under a June 2026 merger agreement, announced on September 8, 2026 that it completed an $835 million financing of debt and equity. The funds will build a 4.5 GW solar cell facility in Laurens County, South Carolina, which the filing says is expected to be completed in late 2027. The filing does not say how the financing affects SUNation's own finances or the merger's timing.
Suniva completed an $835 million capital raise, comprising debt and equity financing, announced September 8, 2026.
Debt includes senior secured credit facilities from funds managed by Goldman Sachs Alternatives and I Squared Capital, plus a second lien facility from JBA Asset Management; equity came from Electron Capital Partners, Orion Infrastructure C
The Laurens County facility is described as a 4.5 GW project with an approximately $600 million investment and 564 anticipated jobs, with completion expected in late 2027.
SUNation and Suniva signed the Merger Agreement on June 5, 2026; the merger remains subject to closing conditions and stockholder and Nasdaq approvals.
Apnimed reported second-quarter 2026 results that swung to net income of $125.9 million, compared with a net loss of $69.5 million a year earlier. The gain was driven by an $85.4 million gain on sale of an equity method investment and a $57.1 million gain on reversal of a deposit liability, while revenue fell to $12.1 million from $17.1 million and the operating loss widened to $11.7 million from $5.9 million. The results also cover the completed IPO, with gross proceeds of $220.8 million, and the FDA's acceptance of the NDA for AD109 (proposed name Oxnimbi) with a PDUFA date of February 28, 2027.
Net income of $125.9 million, or $3.91 per diluted share, versus a net loss of $69.5 million, or $14.61 per share, in Q2 2025
Revenue - related party was $12.1 million versus $17.1 million a year earlier; loss from operations was $11.7 million versus $5.9 million
G&A expenses rose to $12.7 million from $5.4 million, while R&D fell 38% to $9.9 million
Cash and cash equivalents were $172.8 million at June 30, 2026, before the IPO's $220.8 million in gross proceeds
BIO-key International said its 2026 Annual Meeting of Stockholders, convened September 3, 2026, lacked enough votes to approve Proposal 4, which covers issuing up to 1,236,668 shares on exercise of warrants from its August 10, 2026 warrant inducement transaction. The company adjourned the meeting to October 2, 2026, and asked stockholders who have not voted on Proposal 4 to submit a new proxy, which matters because the share issuance is needed to meet Nasdaq listing rules.
Proposal 4 would approve up to 1,236,668 shares for warrants issued in the August 10, 2026 warrant inducement transaction, for Nasdaq Listing Rule 5635(d) purposes.
The Annual Meeting will reconvene on Friday, October 2, 2026, at 10:00 a.m. local time in Holmdel, NJ.
The record date remains July 15, 2026; stockholders who have already voted and do not want to change their vote need not act.
Babcock & Wilcox Enterprises' board approved a dividend of $0.4843750 per share on its 7.75% Series A Cumulative Perpetual Preferred Stock, listed on the NYSE as BW PRA. The record date is September 18, 2026, and payment is due September 30, 2026. This is a routine preferred stock distribution that affects holders of the preferred shares rather than common shareholders.
Dividend of $0.4843750 per share on the 7.75% Series A Cumulative Perpetual Preferred Stock
Record date is September 18, 2026; payment date is September 30, 2026
Preferred Stock trades on the New York Stock Exchange under the symbol BW PRA
MNTN, Inc. said its Board elected Michael J. Katz, a former T-Mobile executive, as a Class II director effective September 3, 2026. The filing says he will serve until the 2027 annual meeting and will receive compensation under the company's non-employee director program and sign its standard indemnification agreement.
Board elected Michael J. Katz as a Class II director effective September 3, 2026, serving until the 2027 annual meeting
Katz most recently served as Chief Business & Product Officer at T-Mobile US from December 2025 to July 2026
He is eligible for the Non-Employee Director Compensation Program described in the April 30, 2026 proxy statement
Amylyx entered a manufacturing and supply agreement with Bachem on September 8, 2026, and a term sheet with Polypeptide Group on September 1, 2026, to supply its long-term commercial needs for avexitide drug substance, if approved. The company will pay Polypeptide a $30 million upfront fee for capacity reservation, and both suppliers are non-exclusive.
Bachem Manufacturing Agreement signed September 8, 2026, with an initial five-year term that renews automatically for three-year periods
Polypeptide Term Sheet signed September 1, 2026, with a $30 million upfront fee for capacity reservation; a definitive agreement is still to be negotiated
Both agreements require minimum annual purchases beginning in 2028, with supply prices adjusted annually
Full agreements will be filed as exhibits to the Form 10-Q for the quarter ending September 30, 2026
Network-1 Technologies' Board of Directors declared a semi-annual cash dividend of $0.05 per common share on September 3, 2026, under its dividend policy. The dividend is payable September 28, 2026 to common stockholders of record as of September 17, 2026. The company states that the dividend policy is reviewed periodically and can change depending on cash position, financial requirements, and earnings.
Dividend amount: $0.05 per common share, semi-annual
Board declaration date: September 3, 2026
Record date: September 17, 2026; payment date: September 28, 2026
Future dividends and dates remain at the Board's discretion and the policy may change
Quantinuum finalized an Other Transaction Agreement with the U.S. Department of Commerce for an award of up to $100 million under the CHIPS Act, with $56 million made available on or about the September 4, 2026 award date and the rest tied to project milestones. On September 8, 2026, the company issued 2,369,528 Class A shares to the Department of Commerce, which adds to the share count held by existing investors and gives the government resale registration rights.
Award of up to $100 million: $56 million available on or about September 4, 2026, with additional $32 million and $12 million payments after milestones.
2,369,528 shares of Class A common stock issued to the Department of Commerce under a Securities Issuance Agreement dated September 8, 2026.
Company agreed to use commercially reasonable efforts to file a resale shelf registration within three months of the agreement.
Department of Commerce may claw back up to the full disbursed award if the company materially fails to meet research security, IP or domestic production requirements.
AEVEX Corp. closed its acquisition of Maritime Applied Physics, LLC, the target that the press release calls BlackSea Technologies, on September 8, 2026. The total enterprise value is $600 million, subject to customary adjustments, and $350 million of it is paid in 12,727,273 newly issued Class A common shares, which dilutes existing shareholders. The filing says the target becomes the company's Maritime Systems division.
Total enterprise value of $600,000,000, subject to customary adjustments; $350,000,000 paid in 12,727,273 Class A common shares
Post-closing adjustment of up to $5,000,000 held in escrow based on net working capital, cash, indebtedness and transaction expenses
Up to $50,000,000 of contingent consideration, payable in additional shares if conditions are met by December 31, 2027, capped at 19.99% of outstanding shares
Target becomes the Maritime Systems division, led by former BlackSea CEO Bob Pudney; financial statements and pro forma information to follow by amendment
Concentra Group Holdings Parent, Inc. (NYSE: CON) said Tanner Newton, its senior vice president of strategy and finance, will become executive vice president and chief financial officer effective November 1, 2026. The change is part of a previously announced leadership succession in which Matthew DiCanio becomes president and chief executive officer and Keith Newton becomes executive chairman on the same date. The filing does not report financial results, and the terms of Tanner Newton's employment agreement will be disclosed in a later filing.
Tanner Newton, 34, was appointed EVP and CFO, effective November 1, 2026; he has been SVP of strategy and finance since January 2025.
Matthew DiCanio, currently president and CFO, becomes president and CEO on November 1, 2026; Keith Newton moves from CEO to executive chairman.
Tanner Newton is the son of Keith Newton, a board member and the current CEO; the company says no arrangements exist under which he was appointed.
Compensation terms are not yet disclosed; the company expects to file an 8-K after the employment agreement is signed.
Inhibikase Therapeutics furnished an updated corporate presentation dated September 2026 for use in meetings with investors and analysts. The filing is a Regulation FD disclosure with no new financial results, guidance, or transaction terms; the presentation restates the company's IKT-001 Phase 3 IMPROVE-PAH development plan and timelines.
Updated corporate presentation dated September 2026 furnished as Exhibit 99.1, issued September 8, 2026
Presentation describes single pivotal Phase 3 IMPROVE-PAH study enrolling across 26 countries and 46 active sites, with a target of about 180 planned sites
Projected timelines include interim safety readout in 1H 2027, unblinded PVR readout in mid 2028, and topline 6MWD readout in mid 2029
Filing states cash runway through Phase 3 Part B topline data readout, assuming full and timely exercise of Series A and B Warrants
IPG Photonics signed a share purchase agreement on September 8, 2026, to acquire Lumibird Medical from Lumibird S.A. for €300 million in cash on a cash-free, debt-free basis, plus up to €50 million in contingent earn-out payments tied to 2026 and 2027 performance metrics. The company expects to fund the deal with cash on hand, and closing is expected in the fourth quarter of 2026, subject to French regulatory approvals and an AMF waiver.
Purchase price of €300 million on a cash-free, debt-free basis, payable in cash at closing, with customary adjustments
Earn-out of up to €50 million in additional cash based on certain 2026 and 2027 performance metrics
Closing subject to French foreign investment authorization and an AMF waiver from a mandatory buyout offer; expected in Q4 2026
Company secured a warranty and indemnity insurance policy covering certain breaches of seller representations
Clearway Energy, Inc. said CFO Sarah Rubenstein will move to a new role at Clearway Energy Group LLC effective October 1, 2026, and Steven Ryder, currently CFO of Clearway Energy Group, will succeed her as CFO of the company. The company also appointed Samantha Prout as senior vice president, accounting and controller, effective September 8, 2026. The filing reports no financial results or guidance; the changes concern the leadership of the company's finance and accounting functions, and Clearway Energy Group held approximately 54.88% of the combined voting power as of June 30, 2026.
Sarah Rubenstein transitions out of her role as CFO effective October 1, 2026, and will become Head of the Transformation Office at Clearway Energy Group LLC.
Steven Ryder, EVP and CFO of Clearway Energy Group since September 2018, becomes CFO of Clearway Energy, Inc. effective October 1, 2026, and keeps his Clearway Energy Group role.
Samantha Prout, formerly Chief Accounting Officer and Controller at Amicus Therapeutics, joins as SVP, Accounting and Controller effective September 8, 2026, and succeeds Rubenstein as principal accounting officer.
Prout will receive a one-time cash sign-on bonus of $50,000.
German American Bancorp's Chairman and CEO D. Neil Dauby and President and CFO Bradley M. Rust will host investor meetings on September 9, 2026, at the Raymond James 2026 U.S. Bank Conference. The attached presentation, furnished as Exhibit 99.1, shows first-half 2026 reported net income of $71.3 million and earnings per share of $1.90, compared with $41.9 million and $1.16 in the same period of 2025.
D. Neil Dauby and Bradley M. Rust will host a series of investor meetings on September 9, 2026.
Six-month 2026 reported net income was $71.3 million, versus $41.9 million in the first half of 2025; reported EPS was $1.90, versus $1.16.
As of June 30, 2026, total assets were $8.4 billion and total loans, net of unearned income, were $5.9 billion.
The presentation is furnished under Item 7.01 and is not deemed filed under Section 18 of the Exchange Act.
Adobe's board appointed Anil Chakravarthy, currently president of the Customer Experience Orchestration business, as president and chief executive officer effective December 1, 2026. Shantanu Narayen, the current chair and CEO, will retire as CEO and become Executive Chair, and David Wadhwani is stepping down as president of the Creativity & Productivity business effective September 27, 2026. The filing contains no financial results, so the change is a leadership transition rather than a change in reported performance.
Anil Chakravarthy named President and CEO and board member, effective December 1, 2026
Shantanu Narayen retires as CEO and becomes Executive Chair of the Board on the same date
David Wadhwani steps down as President, Creativity & Productivity Business, effective September 27, 2026, and remains as a senior advisor for a transition period
Adobe plans to hold its Q3 FY2026 earnings call on September 10
RPC's compensation committee approved higher base salaries for CEO Ben M. Palmer and CFO Michael L. Schmit, retroactive to May 16, 2026. Schmit's 2026 target bonus opportunity also rose to 85% of his base salary, and the company says no other material terms changed.
Palmer's base salary rose from about $637,000 to $750,000
Schmit's base salary rose from about $361,000 to $530,000
Schmit's 2026 target annual cash bonus is now 85% of base salary
Changes approved September 3, 2026, effective retroactively to May 16, 2026
At its September 2, 2026 Annual Meeting, Elite Express Holding's stockholders re-elected five directors, ratified Audit Alliance LLP as auditor for the fiscal year ending November 30, 2026, and approved the 2026 Stock Incentive Plan. The plan reserves an initial 6,000,000 Class A and 2,000,000 Class B shares for awards, which may dilute existing holders over time, though the filing gives no financial results.
Stockholders approved the 2026 Stock Incentive Plan, with an initial reserve of 6,000,000 Class A and 2,000,000 Class B shares, subject to annual increases.
Stockholders re-elected five directors, including Huan Liu and Yidan Chen, each receiving more than 101 million votes for.
Stockholders ratified Audit Alliance LLP as independent registered public accounting firm, with 102,590,571 votes for and 5,379 against.
Filing reports 1,133,134 broker non-votes on the director election and the incentive plan vote.
Quaker Chemical said Executive Vice President, Global Specialty and Chief Growth Officer Jeewat Bijlani will no longer serve in that role effective September 30, 2026. The company said the departure is not related to any disagreement and is treated as a termination without cause under his employment agreement, with severance subject to a customary release of claims.
Jeewat Bijlani's departure as Executive Vice President, Global Specialty and Chief Growth Officer is effective September 30, 2026
The company says the departure is not related to any disagreement with Bijlani
Separation is a termination without cause; severance is subject to a customary release of claims and follows the Company's March 31, 2026 proxy statement terms
Full House Resorts' subsidiary FHR-Illinois and the City of Waukegan, Illinois, signed Amendment No. 1 to their development agreement for the American Place casino on September 2, 2026. The amendment extends the permanent facility's construction completion date to February 17, 2029 and allows the temporary casino structure to be kept in use for five years after the permanent casino opens.
Amendment dated September 2, 2026, formalizes terms the Waukegan City Council approved in July 2026.
Permanent American Place construction completion date extended to February 17, 2029, with operations to begin within three months of completion.
Temporary casino structure may be retained and used for five years beyond the permanent casino's opening.
All other terms of the original January 18, 2023 Development Agreement remain in effect.
Bread Financial signed Amendment No. 2 to its credit agreement with JPMorgan Chase Bank on September 3, 2026, to permit the planned merger of Comenity Bank into Comenity Capital Bank as an exception to certain covenants. The company said the bank merger is not expected to have a significant impact on its consolidated financial position, results of operations, or liquidity, and that the terms of the $700 million revolving credit facility otherwise remain the same.
Amendment No. 2 to Credit Agreement dated September 3, 2026, with JPMorgan Chase Bank, N.A. as administrative agent
Amendment covers the $700 million senior unsecured revolving credit facility, with other terms unchanged
Regulatory approvals for the Bank Merger received July 31, 2026; closing expected on or around October 1, 2026
Alamo Group said on September 8, 2026 that it will stop producing its Boxer branded line of products as part of an ongoing review of its product portfolio. The company estimates approximately $7.0 million to $10.0 million in charges in the third quarter of 2026, and does not expect material cash expenditures tied to the impairment charges.
Decision to cease production of the Boxer branded product line made September 8, 2026
Estimated charges of approximately $7.0 million to $10.0 million, expected in the third quarter of 2026
Company does not expect material cash expenditures; estimates depend on inventory and equipment net realizable value and may change
MIND Technology reported fiscal second-quarter revenue of about $5.6 million for the quarter ended July 31, 2026, down from $13.6 million a year earlier, and a net loss of about $1.7 million, or $0.19 per share, versus net income of $1.9 million, or $0.24 per share, a year earlier. The company said order flow is being hurt by macro uncertainty, and its marine technology product backlog fell to $4.8 million from $12.8 million at July 31, 2025.
Revenue of about $5.6 million, versus $13.6 million in the second quarter of fiscal 2026 and $9.7 million in the first quarter of fiscal 2027
Operating loss of about $1.8 million, versus operating income of $2.7 million a year earlier; Adjusted EBITDA loss of about $949,000, versus $3.1 million a year earlier
Marine technology product backlog for the Seamap segment was $4.8 million at July 31, 2026, down from $12.8 million at July 31, 2025
Company reported $15.8 million in cash and said it is debt-free; conference call scheduled for September 9, 2026 at 9:00 a.m. Eastern Time
Solaris Energy Infrastructure completed its acquisition of Omega Foundation Services, an engineering, procurement and construction firm, through a merger agreement signed and closed on September 1, 2026. The seller, Andrew W. Bennett, received 3,599,199 Class A common shares and about $77 million in cash, subject to post-closing adjustments. The company says the deal adds specialized EPC capabilities to its power infrastructure offering.
Consideration: 3,599,199 Class A common shares plus about $77 million in cash, subject to customary post-closing adjustments
Merger agreement dated September 1, 2026, with the transaction closing the same day
Seller is subject to a 180-day lockup on the shares received, with a longer restriction on a portion of them
Press release of September 2, 2026 cites about $101 million of net cash consideration and $28 million of debt and lease assumption; financial statements and pro forma information to be filed by amendment
Allegion plc said its International president, Tim Eckersley, will retire effective December 31, 2026, after a 40-year career. The board appointed Serge Zappone, currently Allegion APAC general manager, as President, International and Senior Vice President effective January 1, 2027, reporting to CEO John H. Stone. The filing describes an orderly handover, with Eckersley leading the segment through 2026.
Tim Eckersley to step down as President, International and retire effective December 31, 2026
Serge Zappone appointed to succeed him effective January 1, 2027, reporting to CEO John H. Stone
Eckersley will remain in charge of Allegion International through 2026 and work with Zappone on the transition
Zappone joined Allegion in 2020 and has more than 30 years of building products industry experience
TPG Inc. disclosed that President Todd Sisitsky notified the company on September 6, 2026 that he is stepping down as President and from the Board of Directors, effective immediately. The filing does not name a successor or give a reason, so shareholders will be watching for any leadership announcement.
Todd Sisitsky notified TPG of his decision on September 6, 2026
He is leaving his position as President and his seat on the Board of Directors, effective immediately
The filing does not name a replacement or state the reason for the departure
Zimmer Biomet said Kevin Thornal, Group President, Global Businesses and the Americas, will leave the company effective September 30, 2026, as his position is restructured. Gary Campbell, Brian Hatcher and Bradley Kessler were promoted to new roles effective October 1, and the company reiterated its full-year 2026 financial outlook provided on August 5, 2026.
Kevin Thornal's position is restructured and he departs effective September 30, 2026, with severance under the Restated Executive Severance Plan.
Thornal's severance is a lump sum of twelve months of base salary plus target annual bonus, plus twelve months of COBRA premiums, conditioned on a general release.
Gary Campbell becomes President, Americas; Brian Hatcher becomes President, Recon, S.E.T., CMFT, Neuro and Biosurgery; Bradley Kessler becomes President, Americas – Robotics, Technology and Data, all effective October 1.
The company reiterated its full-year 2026 financial outlook provided on August 5, 2026.
Casey's reported first-quarter results for the three months ended July 31, 2026, with net income up 27.1% to $273.7 million and diluted EPS up 27.7% to $7.37. The company said the gains came from higher inside and fuel gross profit, partly offset by higher operating expenses, which rose 8.0%. Its previously disclosed fiscal 2027 outlook remains unchanged, and shareholders elected all 11 director nominees at the September 2 annual meeting.
Diluted EPS was $7.37 versus $5.77 a year earlier; net income was $273.7 million, up 27.1%; EBITDA was $485.1 million, up 17.1%.
Fuel gross profit rose 19.6% to $446.9 million, and inside gross profit rose 6.3% to $749.8 million.
Quarterly dividend of $0.65 per share approved, payable November 13, 2026, to shareholders of record on November 1, 2026.
At the September 2 annual meeting, a shareholder proposal on special meeting rights received 11,445,252 votes for and 17,633,598 against.
Verisk Analytics announced on September 2, 2026 that Chief Human Relations Officer Sunita Holzer will retire. Her retirement date will be set after a successor is identified and announced. The filing does not name a successor or give a financial impact.
Sunita Holzer, Chief Human Relations Officer, will retire from the company.
Holzer joined Verisk in 2021, according to the filing.
Official retirement date to be determined after a successor is announced.
The filing reports no financial results or guidance changes.
Amerant Bancorp entered into an employment agreement with President and CEO Carlos Iafigliola, effective September 4, 2026, running an initial three years. The agreement sets a $875,000 base salary and includes severance terms that depend on whether a termination occurs before or after a change in control.
Initial term runs from September 4, 2026 to the third anniversary, with automatic one-year renewals unless notice of at least 60 days is given
Base salary of $875,000; target annual bonus at least 90% of base salary, maximum at least 135%
Severance before a change in control: two times base salary plus bonus component, paid over 24 monthly installments
Severance after a change in control within 24 months: lump sum of 2.99 times the same measure, subject to banking golden parachute rules
Espey Mfg. & Electronics declared a special cash dividend of $0.75 per share, in addition to a regular quarterly dividend of $0.25 per share, payable September 25, 2026 to holders of record on September 18, 2026. The Board also promoted Kaitlyn O'Neil, who was already principal financial officer and treasurer, to Chief Financial Officer & Treasurer.
Special cash dividend of $0.75 per share, plus regular quarterly dividend of $0.25 per share
Dividends payable September 25, 2026 to shareholders of record on September 18, 2026
Kaitlyn O'Neil promoted to Chief Financial Officer & Treasurer; she previously held the principal financial officer and treasurer roles
On September 8, 2026, Smithfield Foods updated its third quarter 2026 outlook ahead of the Barclays Global Consumer Staples Conference, citing further pressure on the fresh pork market spread and lower hog prices. The company now expects a Fresh Pork third quarter adjusted operating loss of $70 million to $90 million and total company third quarter adjusted operating income of $115 million to $175 million, while reaffirming its fiscal 2026 Packaged Meats outlook. Shareholders will receive updated full-year Fresh Pork, Hog Production and total company guidance with third quarter results.
Fresh Pork third quarter adjusted operating loss now expected at $70 million to $90 million, driven by industry spread compression.
Hog Production third quarter adjusted operating profit now expected at $25 million to $45 million, driven by lower hog prices.
Total company third quarter adjusted operating income expected at $115 million to $175 million.
Packaged Meats fiscal 2026 adjusted operating income outlook of $1.075 billion to $1.15 billion reaffirmed, unchanged from the prior range.
BBOT released new Phase 1 data for BBO-8520 and said it will focus its capital on BBO-8520 plus pembrolizumab in second-line-plus KRAS G12C inhibitor-experienced lung cancer and on BBO-11818 and BBO-10203 combinations in KRAS-mutant cancers. The attached corporate presentation says BBO-8520 in first-line NSCLC and BBO-10203 in breast cancer have been deprioritized, with no near-term plans for further investment. For shareholders, the filing narrows the pipeline focus, and the company projects its $344.1 million in cash will fund operations into 2028.
BBO-8520 plus pembrolizumab showed a 75% objective response rate at the 500 mg once-daily dose and 53% across all dose levels (N=17) in the ONKORAS-101 study, with a June 1, 2026 data cutoff.
Cash, cash equivalents and marketable securities were $344.1 million as of June 30, 2026, which the company projects will fund operations into 2028.
BBO-11818 and BBO-10203 monotherapy data update is expected in Q4 2026; expanded BBO-8520 plus pembrolizumab data is expected in mid-2027.
The corporate presentation says BBO-8520 in 1L NSCLC and BBO-10203 in breast cancer have been deprioritized, with no near-term plans for further investment.
Satellogic's Board approved the appointment of Frank Dixon Whitworth III as President, effective September 7, 2026. Whitworth is a retired U.S. Navy Vice Admiral who served as Director of the National Geospatial-Intelligence Agency from June 2022 until his retirement in December 2025, and he has been a strategic advisor to the company since March 2026. His offer letter sets out pay and severance terms, which shareholders can review in the 10-Q filing for the period ending September 30, 2026.
Board approved the appointment on September 4, 2026, effective September 7, 2026.
Offer letter provides a $400,000 annual base salary and a $240,000 target annual performance bonus.
First-year restricted stock unit grant has a grant date value of $1,875,000, vesting quarterly over five years.
If terminated without cause outside a change of control, he receives six months of base salary, a prorated bonus and some equity acceleration.
Shutterstock said its board appointed Timothy Adams, Matthew Salzberg and Michael Thompson as directors, effective September 8, 2026. The board determined that all three are independent under SEC rules and NYSE listing standards, and none has been placed on a board committee yet.
Board appointed the three directors on September 4, 2026, effective September 8, 2026.
Adams and Salzberg are Class II directors with terms expiring at the 2026 annual meeting; Thompson is a Class III director with a term expiring at the 2027 annual meeting.
Adams is CFO of Validity Inc. and previously was CFO of Rapid7, Inc.; Salzberg founded Blue Apron and led its 2017 IPO.
New directors receive the same compensation as the company's other non-employee directors.
Mission Produce reported fiscal third-quarter 2026 results for the quarter ended July 31, 2026. Revenue rose 26% to $450.0 million, but the company posted a net loss attributable to Mission Produce of $6.5 million, or $(0.08) per diluted share, including $25.4 million of pre-tax Calavo acquisition-related costs, compared with income of $14.7 million, or $0.21 per share, a year earlier. The company reaffirmed its second-half fiscal 2026 Adjusted EBITDA outlook of $84 million to $88 million and raised its estimated annualized Calavo synergy opportunity to more than $30 million.
Revenue $450.0 million, up 26%; avocado volume up 38% and per-unit prices down 9%
Net loss attributable to Mission Produce $6.5 million, or $(0.08) per diluted share, versus income of $14.7 million, or $0.21, a year earlier
Adjusted net income $15.0 million, or $0.18 per diluted share, versus $18.2 million, or $0.26, a year earlier
Second-half fiscal 2026 Adjusted EBITDA outlook of $84 million to $88 million reaffirmed; fourth-quarter Adjusted EBITDA expected at $52 million to $55 million
Adicet Bio posted a September 2026 investor presentation to its website and furnished it as Exhibit 99.1 to a Form 8-K. The deck covers its prula-cel autoimmune program, its ADI-212 solid tumor candidate and its in vivo CAR-T pipeline, and sets out expected clinical and regulatory milestones.
ADI-212 has an IND cleared in the US, with first-patient dosing anticipated in 4Q26 and clinical data expected in 1H27 and 2H27.
Prula-cel clinical data cited in the deck has a cut-off date of August 31, 2025 and covers 7 patients (5 LN and 2 SLE) with follow-up of 2-9 months.
The filing describes a CRISPR license for ADI-212 gene-editing technology, with CRISPR holding an opt-in right to a 50/50 cost and profit split.
The fund implemented a 1-for-3 reverse stock split on September 4, 2026, so every three common shares became one. Its September monthly distribution was adjusted from $0.06 to $0.18 per share, but the total cash paid to shareholders for September is unchanged, and the filing says the split does not change the total value of shareholders' investments.
Split took effect after close of business on September 4, 2026; shares continue to trade on the NYSE under IGR.
Per-share monthly distribution adjusted from $0.06 to $0.18; total September cash unchanged.
New CUSIP 12504G878 replaces 12504G100; September ex-dividend and record dates are 09-21-2026 and payable date is 09-30-2026.
Fractional shares are aggregated and sold on the NYSE, with proceeds paid pro rata to affected shareholders.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.